vs
Digimarc CORP（DMRC）与Xilio Therapeutics, Inc.（XLO）财务数据对比。点击上方公司名可切换其他公司
Xilio Therapeutics, Inc.的季度营收约是Digimarc CORP的1.5倍（$13.7M vs $8.9M），Xilio Therapeutics, Inc.净利率更高（75.7% vs -47.2%，领先122.9%），Digimarc CORP自由现金流更多（$895.0K vs $-2.1M）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
Xilio Therapeutics是一家临床阶段生物技术企业，专注开发用于多种癌症治疗的新型肿瘤选择性免疫疗法，其在研候选药物可在肿瘤微环境中特异性激活抗肿瘤免疫反应，降低全身性毒副作用，主要面向北美及全球其他地区的肿瘤患者群体。
DMRC vs XLO — 直观对比
营收规模更大
XLO
是对方的1.5倍
$8.9M
净利率更高
XLO
高出122.9%
-47.2%
自由现金流更多
DMRC
多$3.0M
$-2.1M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $13.7M |
| 净利润 | $-4.2M | $10.4M |
| 毛利率 | 63.5% | — |
| 营业利润率 | -48.2% | -86.5% |
| 净利率 | -47.2% | 75.7% |
| 营收同比 | 2.9% | — |
| 净利润同比 | 51.4% | 179.1% |
| 每股收益（稀释后） | $-0.18 | $-3.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCXLO
| Q4 25 | $8.9M | $13.7M | ||
| Q3 25 | $7.6M | $19.1M | ||
| Q2 25 | $8.0M | $8.1M | ||
| Q1 25 | $9.4M | $2.9M | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $10.4M | — | ||
| Q1 24 | $9.9M | — |
净利润DMRCXLO
| Q4 25 | $-4.2M | $10.4M | ||
| Q3 25 | $-8.2M | $-16.3M | ||
| Q2 25 | $-8.2M | $-15.8M | ||
| Q1 25 | $-11.7M | $-13.3M | ||
| Q4 24 | $-8.6M | — | ||
| Q3 24 | $-10.8M | — | ||
| Q2 24 | $-9.3M | — | ||
| Q1 24 | $-10.3M | — |
毛利率DMRCXLO
| Q4 25 | 63.5% | — | ||
| Q3 25 | 58.3% | — | ||
| Q2 25 | 58.8% | — | ||
| Q1 25 | 65.0% | — | ||
| Q4 24 | 60.8% | — | ||
| Q3 24 | 62.4% | — | ||
| Q2 24 | 66.1% | — | ||
| Q1 24 | 62.5% | — |
营业利润率DMRCXLO
| Q4 25 | -48.2% | -86.5% | ||
| Q3 25 | -109.7% | -10.1% | ||
| Q2 25 | -105.2% | -177.7% | ||
| Q1 25 | -128.9% | -472.7% | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -120.4% | — | ||
| Q2 24 | -96.2% | — | ||
| Q1 24 | -109.2% | — |
净利率DMRCXLO
| Q4 25 | -47.2% | 75.7% | ||
| Q3 25 | -106.9% | -85.4% | ||
| Q2 25 | -102.6% | -196.0% | ||
| Q1 25 | -125.2% | -452.7% | ||
| Q4 24 | -99.9% | — | ||
| Q3 24 | -113.9% | — | ||
| Q2 24 | -89.3% | — | ||
| Q1 24 | -104.0% | — |
每股收益（稀释后）DMRCXLO
| Q4 25 | $-0.18 | $-3.74 | ||
| Q3 25 | $-0.38 | $-0.11 | ||
| Q2 25 | $-0.38 | $-0.16 | ||
| Q1 25 | $-0.55 | $-0.18 | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.50 | — | ||
| Q2 24 | $-0.43 | — | ||
| Q1 24 | $-0.50 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $40.2M | $35.3M |
| 总资产 | $53.0M | $154.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DMRCXLO
| Q4 25 | $12.9M | $137.5M | ||
| Q3 25 | $12.6M | $103.8M | ||
| Q2 25 | $16.1M | $121.6M | ||
| Q1 25 | $21.6M | $89.1M | ||
| Q4 24 | $28.7M | — | ||
| Q3 24 | $33.7M | — | ||
| Q2 24 | $41.5M | — | ||
| Q1 24 | $48.9M | — |
股东权益DMRCXLO
| Q4 25 | $40.2M | $35.3M | ||
| Q3 25 | $41.4M | $-8.1M | ||
| Q2 25 | $46.5M | $7.1M | ||
| Q1 25 | $50.0M | $10.7M | ||
| Q4 24 | $61.4M | — | ||
| Q3 24 | $70.2M | — | ||
| Q2 24 | $77.2M | — | ||
| Q1 24 | $84.5M | — |
总资产DMRCXLO
| Q4 25 | $53.0M | $154.7M | ||
| Q3 25 | $55.4M | $133.7M | ||
| Q2 25 | $60.7M | $133.8M | ||
| Q1 25 | $66.5M | $103.7M | ||
| Q4 24 | $75.8M | — | ||
| Q3 24 | $85.0M | — | ||
| Q2 24 | $93.4M | — | ||
| Q1 24 | $99.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | $895.0K | $-2.1M |
| 自由现金流率自由现金流/营收 | 10.0% | -15.3% |
| 资本支出强度资本支出/营收 | 1.1% | 0.7% |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | $-12.3M | — |
8季度趋势，按日历期对齐
经营现金流DMRCXLO
| Q4 25 | $991.0K | $-2.0M | ||
| Q3 25 | $-2.6M | $-17.5M | ||
| Q2 25 | $-4.7M | $-14.5M | ||
| Q1 25 | $-5.5M | $29.0M | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-7.1M | — | ||
| Q2 24 | $-6.8M | — | ||
| Q1 24 | $-8.4M | — |
自由现金流DMRCXLO
| Q4 25 | $895.0K | $-2.1M | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-4.9M | $-14.9M | ||
| Q1 25 | $-5.5M | $29.0M | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $-8.5M | — |
自由现金流率DMRCXLO
| Q4 25 | 10.0% | -15.3% | ||
| Q3 25 | -36.9% | — | ||
| Q2 25 | -61.0% | -184.0% | ||
| Q1 25 | -59.1% | 988.3% | ||
| Q4 24 | -49.1% | — | ||
| Q3 24 | -75.7% | — | ||
| Q2 24 | -66.1% | — | ||
| Q1 24 | -85.8% | — |
资本支出强度DMRCXLO
| Q4 25 | 1.1% | 0.7% | ||
| Q3 25 | 2.9% | 0.0% | ||
| Q2 25 | 2.5% | 5.0% | ||
| Q1 25 | 0.6% | 0.8% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.1% | — |
现金转化率DMRCXLO
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
XLO
暂无分部数据
